Tranexamic Acid: An Evergreen Hemostatic Agent

Abstract

Tranexamic acid (TXA) is an important antifibrinolytic agent, which inhibits plasminogen activation and fibrinolysis. Several controlled randomized trials have investigated the role of TXA in preventing or decreasing blood loss across different surgical interventions or medical conditions characterized by excessive bleeding, consistently documenting its effectiveness and safety. Although the first clinical use of TXA dates back to more than 60 years ago, TXA remains the focus of intense research. This narrative review summarizes the more recent results and indications on the clinical use of TXA.

Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part IV

“…Next is a short historical review from Franchini and coworkers 9 on tranexamic acid, a hemostatic agent used as adjunct therapy in a wide range of bleeding conditions or disorders, including both VWD and hemophilia A. Tranexamic acid is an important antifibrinolytic agent, which inhibits plasminogen activation and fibrinolysis. Several RCTs have investigated the role of tranexamic acid in preventing or decreasing blood loss across different surgical interventions or medical conditions characterized by excessive bleeding, consistently documenting its effectiveness and safety.…”